Literature DB >> 26455677

Bioequivalence of generic drugs.

Chittaranjan Andrade1.   

Abstract

Generic drugs are bioequivalent to the original brand; this is a prerequisite for marketing approval. It is theoretically possible that one generic drug may overestimate the pharmacokinetic (PK) parameters of the original and another generic may underestimate these PK parameters; in consequence, these 2 generics may not be bioequivalent between themselves. The result could be loss of efficacy or development of drug-related adverse effects if these generics are interchanged in stable patients. In a recent study involving 292 indirect comparisons of generic formulations of 9 different drugs, mathematical modeling showed that in most cases (87.0% for maximum concentration, 90.1% for area under the curve, and 80.5% for both) generic drugs are bioequivalent to each other. These reassuring findings notwithstanding, prudence dictates that, in stable patients, generic drugs should be interchanged only if there is a good reason for it. This is because bioequivalent brands of drugs may differ in their excipient content, and this can result in variations in safety profiles. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26455677     DOI: 10.4088/JCP.15f10300

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  Prescription writing: Generic or brand?

Authors:  Chittaranjan Andrade; T S Sathyanarayana Rao
Journal:  Indian J Psychiatry       Date:  2017 Apr-Jun       Impact factor: 1.759

2.  The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.

Authors:  Erin Hillhouse; Karine Mathurin; Joëlle Bibeau; Diana Parison; Yasmine Rahal; Jean Lachaine; Catherine Beauchemin
Journal:  Adv Ther       Date:  2021-11-15       Impact factor: 3.845

Review 3.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

Review 4.  The use of GA-RxODE (Genetics Algorithms and Running simulations from Ordinary Differential Equations-based model) method to optimize bioequivalence studies.

Authors:  Ezequiel Omar Nuske; Mikhail Morozov; Héctor Alejandro Serra
Journal:  Pharmacol Res Perspect       Date:  2021-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.